Employers and Pharma: What’s New Under the Sun
Prescription drugs can mean life-changing outcomes for patients – and soaring costs. What’s going to lessen this burden for employers and employees alike? And what can you do right now to seek relief? Find out on July 17!
Wednesday, July 17, 2019
Arrival and Breakfast
Welcome and Introductions
Pharma Supply Chain Disruption: Is it Real and Does it Matter to Employers?
Josh GoldenSolid Benefit Guidance
There’s a lot going on – PBM and health plan consolidation, drug pricing legislation and new rebate rules from Washington, D.C. Plus we’re hearing about Amazon’s PillPack acquisition and Haven – the Amazon/Berkshire Hathaway/JPMorgan Chase health venture. But will anything really change for employers?
Reaping the Cost-Saving Benefits of Biosimilars
James Dolan PhD
Biosimilars exist for costly conditions like RA and cancer, but obstacles exist to access and uptake by employers. What, exactly, are biosimilars, and what do YOU need to do to achieve the cost-saving benefits?
- Biologics and biosimilars: what are they and what’s the difference?
- Which biosimilars can save you money right now – and how much?
- What are PBMs and health plans doing with biosimilars, and what are the obstacles to full-scale use by employees?
- Call to action for employers: Here’s what to do now!
Managing Costs through Data: Mining the Trove
Thomas C. Squires, Esq.
Mining your data can give you insights that lead to cost savings. Audits can uncover costly errors and yield significant returns, especially when it comes to rebates. How can employers use data analytics to generate efficiencies and hold PBMs accountable?
Boosting Value through Prescription Guidance and Employee Engagement
Is it possible to reduce drug costs while also enhancing the patient experience? New solutions offer you savings opportunities without needing to change your PBM partner.
Holistic Specialty Rx: Health Plan/PBM Approaches
How should employers be thinking about specialty Rx from both the medical and PBM sides? Is a holistic strategy in the cards from consolidated entities?
Pulling Open the Curtain on the Pharma Supply Chain
This investigative reporter goes behind the scenes to dig up truth. What has he found when it comes to employers and the pharma supply chain?